Procopius in comments yesterday raised a point I’ve seen around a couple of times that I want to address as the logic is internally inconsistent with a core underlying assumption of the statement. I believe all the pharma companies have one thing in common. I believe they search for treatments that ameliorate, but do not […]
About David Anderson
I'm a research associate at Duke University Margolis Center. I used to be Richard Mayhew, a mid-level bureaucrat at UPMC Health Plan. I started writing here and have not found a reason to stop.
Entries by David Anderson
Bloomberg has a good article from earlier this week that is looking at the genetic treatments that are in the pipeline that may be long term cures for rare and expensive to treat diseases. The most important paragraph from a policy perspective is the outlay/benefit dissonance: The new therapies aim to fix the root causes […]
Great news in Louisiana. A new pricing model was approved about two weeks ago for the Hepatitis-C anti-virals. The state will be engaging a single manufacturer for a no marginal cost subscription model of the Hep-C cures for two large populations at need. The state Secretary of Health explains some more in the Health Affairs […]
This tweet below is a fairly common experience: I don't usually get hung up about titles, but boy does it irk me when an introduction goes something like "I'd like to introduce Dr. Man 1, Dr. Man 2, and Melissa Garrido". Don't do this! — Melissa Garrido (@GarridoMelissa) April 4, 2019 I have seen this […]
The Center for Medicare and Medicaid Services (CMS) released a proposed rule on funding the Basic Health Plan (BHP) for 2020. They propose a rule that will lead to about a 3% reduction in federal spending to be counter-acted by a dollar for dollar increase in state spending. BHPs are a part of the Affordable […]